hotspot -WSS

hotspot

author：entertainment 2025-09-30 20:47:42 - browse：6

An army of wooden figures under blue and pink lighting — biotech coverage from STAT — Adobe

Biotech startup ReNAgade Therapeutics is cutting staff just seven months after raising the largest Series A round in the industry this year.

ReNAgade launched in May with hopes of becoming a one-stop shop for medicines targeting RNA, the genetic blueprints that cells use to make proteins instrumental in numerous diseases. These types of medicines are in high demand following the advent of mRNA vaccines for Covid and RNA-silencing therapies made by companies like Alnylam Pharmaceuticals.

ReNAgade was able to capitalize on that excitement when it raised a $300 million Series A round led by MPM Capital’s BioImpact Capital and F2 Ventures. But in recent days, the company decided to lay off around 10% of its 100-person team, according to a company statement and former employees’ posts on social media.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Affirmative action in medical school literally saved lives
Next article： The pain doctors face in trying to build their families

entertainment

WSS

Readout LOUD: Venture capital, Gilead, and more M&A

Novo Holdings to buy drug manufacturer Catalent in $16.5B deal

Ukraine taking heavy casualties 10 weeks into its counteroffensive

Problems with a popular proposal to regulate AI in health care

Living with Hashimoto's and celiac disease, and med school, too

The CDC's new social media misinformation war

entertainment

hotspot

hotspot

Medical leaders decry Supreme Court decision on affirmative action

The Biogen Aduhelm mess could happen again

Tori Bowie and the unacceptable rates of Black maternal death

Beware the threat of staffing cuts at the CDC

Duchenne breakthrough therapy leaves behind pioneering families

Beware the threat of staffing cuts at the CDC

Medicare details structure of new drug price negotiation program

Updated Covid vaccine has 54% effectiveness, new study suggests

As demand for Covid shots wanes, Moderna seeks its next success

A protest over insulin prices is seen as a fight for life

leisure time

ActiGraph execs on goal of drug approvals with digital endpoints

ProMED sees offers of support, but its future remains unclear

The Biogen Aduhelm mess could happen again

Clinical trials must include more disabled people

Johnson & Johnson sued for allegedly overpaying for workers' drugs

New definition of a human embryo proposed amid rapid advances

knowledge

knowledge

entertainment

explore